These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2532697)

  • 1. Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP; Neff NH
    Life Sci; 1989; 45(25):2495-502. PubMed ID: 2532697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP; Neff NH
    Neurosci Lett; 1988 Oct; 92(2):207-12. PubMed ID: 2903475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
    Schneider JS; DiStefano L
    Neuroreport; 1993 Nov; 5(2):103-4. PubMed ID: 8110995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPTP-induced parkinsonism: acceleration of biochemical and behavioral recovery by GM1 ganglioside treatment.
    Schneider JS
    J Neurosci Res; 1992 Jan; 31(1):112-9. PubMed ID: 1613817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover.
    Vital MA; Flório JC; Frussa-Filho R; De Lucia R; Tufik S; Palermo-Neto J
    Life Sci; 1998; 62(13):1161-9. PubMed ID: 9519797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of GM1 ganglioside treatment on dopamine innervation of the striatum of MPTP-treated mice.
    Rothblat DS; Schneider JS
    Ann N Y Acad Sci; 1998 Jun; 845():274-7. PubMed ID: 9668361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse.
    Hadjiconstantinou M; Neff NH
    J Neurochem; 1988 Oct; 51(4):1190-6. PubMed ID: 3262149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation between biochemical and behavioral recovery in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP
    Pharmacol Biochem Behav; 1989 Sep; 34(1):113-7. PubMed ID: 2696981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP.
    Hadjiconstantinou M; Rossetti ZL; Paxton RC; Neff NH
    Neuropharmacology; 1986 Sep; 25(9):1075-7. PubMed ID: 3490632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
    Pope-Coleman A; Tinker JP; Schneider JS
    Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
    Schneider JS
    Neuropharmacology; 1992 Feb; 31(2):185-92. PubMed ID: 1553028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
    Schneider JS; Pope A; Simpson K; Taggart J; Smith MG; DiStefano L
    Science; 1992 May; 256(5058):843-6. PubMed ID: 1350379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
    Rothblat DS; Schneider JS
    Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP
    Neurosci Lett; 1988 Feb; 85(1):137-42. PubMed ID: 3258974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential recovery of sensorimotor function in GM1 ganglioside-treated vs. spontaneously recovered MPTP-treated cats: partial striatal dopaminergic reinnervation vs. neurochemical compensation.
    Schneider JS; Schroeder JA; Rothblat DS
    Brain Res; 1998 Nov; 813(1):82-7. PubMed ID: 9824674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
    Hadjiconstantinou M; Mariani AP; Neff NH
    Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
    Fazzini E; Durso R; Davoudi H; Szabo GK; Albert ML
    J Neurol Sci; 1990 Oct; 99(1):59-68. PubMed ID: 2250172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with GM1 ganglioside reverses dopamine D-2 receptor supersensitivity induced by the neurotoxin MPTP.
    Hadjiconstantinou M; Weihmuller F; Neff NH
    Eur J Pharmacol; 1989 Sep; 168(2):261-4. PubMed ID: 2532603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous GM1 gangliosides induce partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice.
    Date I; Felten SY; Felten DL
    Neurosci Lett; 1989 Dec; 106(3):282-6. PubMed ID: 2601883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium.
    Miller DB; Reinhard JF; Daniels AJ; O'Callaghan JP
    J Neurochem; 1991 Aug; 57(2):541-9. PubMed ID: 1649252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.